NAME and CONTACT DETAILS

Cédric Logé, Ph.D., Associate Professor (HDR) Phone: +33 (0)2 53 00 91 54
Nantes Université - IICIMED-UR1155 - Département de Chimie Thérapeutique
Institut de Recherche en Santé 2, 22 Boulevard Bénoni Goullin, 44200 Nantes, France
E-mail : cedric.loge@univ-nantes.fr

CAREER PROFILE

Education

Ability to supervise Research (HDR) in Medicinal Chemistry, University of Nantes, France (2016)
Ph.D. in Medicinal Chemistry - Thesis title: "Design and Synthesis of Rho-kinase inhibitors" (Adviser: Pr. Daniel Lesieur), University of Lille, France (2002)
MSc (Mastère) in Drug Design, ICPAL, ENSCL, University of Lille, France (1999)
Master's degree (DEA) in Organic Chemistry**,** Pasteur Institute (Adviser: Pr. Christian Sergheraert) and University of Lille, France (1997)

Experience

2016-present: Senior lecturer/Associate Professor of Medicinal Chemistry, University of Nantes, France
2004-2016: Lecturer/Assistant Professor of Medicinal Chemistry, University of Nantes, France
2003-2004: Research and Teaching Assistant (ATER), University of Nantes, France
2002-2003: Postdoctoral Position in Molecular Modeling (Adviser: Pr. Philippe Chavatte), University of Lille, France

Teaching Experience

Teaching of Organic Chemistry (practical courses) and Medicinal Chemistry (antivirals, antimalarials, antifungals, kinase inhibitors) at the Faculty of Pharmacy (2nd to 5th years of study). Teaching of Molecular Modeling in Drug Design (Master's degree).

RESEARCH

Main areas of interest

In silico design (docking) and synthesis of new enzyme inhibitors in (1) oncology (protein kinase inhibitors) and (2) infectious diseases (fungal CYP51 inhibitors and protein kinase inhibitors).

Doctoral supervision

4 PhD students, 10 Master's degree.

Valorization

43 publications (*h*-index scopus: 18, citations: 927), 1 patent, 12 oral communications and invited lectures.

Selected publications

1. Discovery of a novel broad-spectrum antifungal agent, derived from albaconazole. R. Guillon, F. Pagniez, C. Picot, D. Hedou, A. Tonnerre, E. Chosson, M. Duflos, T. Besson, **C. Logé**,* P. Le Pape. *ACS Medicinal Chemistry Letters*, **2013**, 4, 288-292.
2. Synthesis of new pyridazino[4,5-*b*]indol-4-ones and pyridazin-3(2*H*)-one analogs as DYRK1A inhibitors. A. Bruel, R. Bénéteau, M. Chabanne, O. Lozach, R. Le Guével, M. Ravache, H. Bénédetti, L. Meijer, **C. Logé**,* J.-M. Robert. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 5037-5040.
3. Synthesis and molecular modelling studies of 8-arylpyrido[3′,2′:4,5]thieno[3,2-*d*]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors. Y. Loidreau, E. Deau, P. Marchand, M.R. Nourrisson, **C. Logé**, G. Coadou, N. Loaec, L. Meijer, T. Besson. *European Journal of Medicinal Chemistry*, **2015**, 92, 124-134.
4. Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors. B. Oyallon, M. Brachet-Botineau, **C. Logé**, P. Bonnet, M. Souab, T. robert, S. Ruchaud, S. Bach, P. Berthelot, F. Gouilleux, M.-C. Viaud-Massuard, C. Denevault-Sabourin. *European Journal of Medicinal Chemistry*, **2018**, 154, 101-109. Cover image, Eur. J. Med. Chem., Vol.154
5. New azole antifungals with a fused triazinone scaffold. D. Montoir, R. Guillon, S. Gazzola, I. Ourliac-Garnier, K. E. Soklou, A. Tonnerre, C. Picot, A. Planchat, F. Pagniez, P. Le Pape, **C. Logé**.* *European Journal of Medicinal Chemistry*, **2020**, 189, 112082.

Patent awarded

Novel fused pyrimidinone and triazinone derivatives, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents. **C. Logé**, R. Guillon, D. Montoir, F. Pagniez, P. Le Pape. PCT WO **2017**/020944 A1.